Stem Cell Sources Used for HSCT Vary by Country, Resources

Share this content:
Stem Cell Sources Used for HSCT Vary by Country, Resources
Stem Cell Sources Used for HSCT Vary by Country, Resources

WEDNESDAY, Jan. 13, 2016 (HealthDay News) -- Use of bone marrow as the stem cell source for hematopoietic stem cell transplantation (HSCT) increases with increasing incomes, according to a research letter published in the Jan. 12 issue of the Journal of the American Medical Association.

Ayami Yoshimi, M.D., Ph.D., from the University of Freiburg in Germany, and colleagues examined the use of peripheral blood stem cells (PBSCs) and bone marrow as stem cell sources for HSCT in patients with bone marrow failure. Data were included from retrospective HSCT surveys for 74 member states of the World Health Organization that performed at least one HSCT during 2009 to 2010.

The researchers found that 3,282 allogeneic HSCTs were performed for bone marrow failure among 114,217 HSCTs reported by 1,482 transplant teams. The stem cell sources were bone marrow, PBSCs, and cord blood (54, 41, and 5 percent, respectively). Bone marrow was used in 57 percent of the 3,102 HSCTs (excluding cord blood). The use of bone marrow was most common in the Americas (75 percent) and Europe (60 percent). Use of bone marrow increased with increasing incomes (20 percent in countries with low and low-middle incomes, 50 percent with high-middle incomes, and 64 percent with high incomes; P < 0.001).

"This study showed that the stem cell source used for HSCT for bone marrow failure varied worldwide, with PBSCs being used more frequently in regions with limited resources," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »